Randomized phase II trials: a long-term investment with promising returns

Area of Science:

• Oncology
• Clinical Trial Design
• Drug Development

Background:

• Current single-arm phase II trials in oncology face limitations due to historical controls, leading to bias and confounding.
• The low success rate (40%) of phase III oncology trials indicates that phase II evaluations are often insufficiently informative.

Purpose of the Study:

• To advocate for the adoption of randomized phase II trials in oncology.
• To highlight the advantages of randomized phase II trials over single-arm designs for predicting phase III success.

Main Methods:

• Review of existing literature and simulation studies comparing single-arm and randomized phase II trial designs.
• Discussion of various randomized phase II designs, including adaptive and selection designs.
• Analysis of barriers to the adoption of randomized phase II trials.

Main Results:

• Randomized phase II trials demonstrate lower error rates and enhanced predictive power for phase III outcomes compared to single-arm trials.
• Randomized designs offer greater informativeness through hypothesis testing, diverse endpoints, and biomarker discovery.
• Identified barriers such as trial duration and sample size are surmountable.

Conclusions:

• Randomized phase II trials are a more effective and informative approach for evaluating novel oncology therapies.
• Widespread adoption of randomized phase II trials is recommended to optimize patient and financial resources in drug development.
• These trials should become the standard rather than the exception in oncology research.